SBFM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
9.4M
+1.9%
9.3M
+14.5%
8.1M
-5.7%
8.6M
-8.9%
9.4M
Cost of Revenue
6.3M
-7.3%
6.8M
+15.7%
5.9M
+6.5%
5.5M
-12.5%
6.3M
Gross Profit
3.1M
+27.8%
2.4M
+11.3%
2.2M
-28.0%
3.0M
-1.5%
3.1M
Operating Expenses
4.4M
+8.7%
4.0M
+12.9%
3.6M
-25.8%
4.8M
+15.8%
4.2M
R&D
1.6K
-88.2%
13.2K
-58.3%
31.7K
-56.8%
73.5K
-38.4%
119.3K
SG&A
3.1M
-0.5%
3.2M
+1.7%
3.1M
-21.9%
4.0M
+36.3%
2.9M
Operating Income
-1290492
+20.0%
-1612858
-15.6%
-1395597
+22.0%
-1790011
-64.7%
-1086613
EBITDA
-827364
+31.3%
-1203881
+2.1%
-1229662
+15.8%
-1459703
-500.6%
-243043
Net Income
-1223940
+21.7%
-1564048
-25.7%
-1243869
+41.9%
-2140927
-142.2%
-883820
EPS (Basic)
$-5.20
+77.4%
$-23.00
+54.0%
$-50.00
+43.1%
$-87.87
-126.5%
$-38.80
EPS (Diluted)
$-5.20
+77.4%
$-23.00
+54.0%
$-50.00
+43.1%
$-87.87
-126.5%
$-38.80
Shares (Diluted)
235.3K
+244.7%
68.3K
+178.3%
24.5K
+0.7%
24.4K
+7.0%
22.8K
Sunshine Biopharma (SBFM) — Financials